Biostax Corp.
Biostax Corp. (BTAX): 4 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.6 months
D/E -1.00 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for Biostax Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8K
Cash
$5K
Quarterly Burn
$2K
Runway
7.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| jkb-122 | Preclinical |
| lodonal | Approved |
| low dose naltrexone | Preclinical |
| menk | — |
Frequently asked questions
How many drug candidates are in Biostax Corp.'s pipeline?
Biostax Corp. (BTAX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Biostax Corp.'s lead drug candidate?
Biostax Corp.'s most advanced tracked candidate is jkb-122 (Preclinical) for Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
What is Biostax Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Biostax Corp. has approximately 7.6 months of cash runway.
What is Biostax Corp.'s market capitalization?
Biostax Corp.'s market capitalization is approximately $8K.
Who is the CEO of Biostax Corp.?
Ms. Noreen M. Griffin is the chief executive officer of Biostax Corp. (BTAX).
Get the full picture on Biostax Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.